View Filing Data

Document and Entity Information Document - USD ($)	6 Months Ended
Document and Entity Information Document - USD ($)	Jun. 30, 2012	Aug. 03, 2012	Jun. 30, 2011
Entity Registrant Name	BioScrip, Inc.
Entity Central Index Key	0001014739
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Document Type	10-Q
Document Period End Date	Jun. 30, 2012
Document Fiscal Year Focus	2012
Document Fiscal Period Focus	Q2
Amendment Flag	false
Entity Common Stock, Shares Outstanding		59,116,532
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Public Float			$ 184,882,882

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jun. 30, 2012	Dec. 31, 2011
Current assets
Cash and cash equivalents	$ 138,423	$ 0
Receivables, less allowance for doubtful accounts	146,469	225,412
Inventory	21,242	17,997
Prepaid expenses and other current assets	5,725	10,184
Current assets from discontinued operations	0	38,876
Total current assets	311,859	292,469
Property and equipment, net	20,857	26,951
Goodwill	312,387	312,387
Intangible assets, net	18,058	19,622
Deferred financing costs	3,353	3,992
Investments in and advances to unconsolidated joint ventures	6,949	0
Other non-current assets	1,455	1,552
Non-current assets from discontinued operations	0	20,129
Total assets	674,918	677,102
Current liabilities
Current portion of long-term debt	31,230	66,161
Accounts payable	28,842	79,155
Claims payable	10,906	11,766
Amounts due to plan sponsors	25,681	25,219
Accrued interest	5,845	5,825
Accrued expenses and other current liabilities	36,493	32,648
Total current liabilities	138,997	220,774
Long-term debt, net of current portion	226,216	227,298
Deferred taxes	9,008	10,295
Other non-current liabilities	5,798	3,456
Total liabilities	380,019	461,823
Stockholders' equity
Preferred stock	0	0
Common stock	6	6
Treasury stock	(10,311)	(10,461)
Additional paid-in capital	385,931	375,525
Accumulated deficit	(80,727)	(149,791)
Total stockholders' equity	294,899	215,279
Total liabilities and stockholders' equity	$ 674,918	$ 677,102

PARENTHETICAL DATA TO CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jun. 30, 2012	Dec. 31, 2011
Current assets
Allowance for doubtful accounts	$ 22,719	$ 22,728
Stockholders' equity
Preferred stock, par value	$ 0.00	$ 0.00
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.00	$ 0.00
Common stock, shares authorized	125,000,000	125,000,000
Common stock, shares issued	59,115,499	57,800,791
Common stock, shares outstanding	56,534,396	55,109,038
Treasury stock, shares at cost	2,582,520	2,638,421

UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2012	Jun. 30, 2011	Jun. 30, 2012	Jun. 30, 2011
Product revenue	$ 108,557	$ 87,717	$ 215,360	$ 177,499
Service revenue	47,344	43,858	96,174	84,913
Revenue	155,901	131,575	311,534	262,412
Cost of product revenue	75,120	56,667	147,446	114,276
Cost of service revenue	27,740	23,078	57,525	44,954
Cost of revenue	102,860	79,745	204,971	159,230
Gross profit	53,041	51,830	106,563	103,182
Selling, general and administrative expenses	44,692	40,430	89,354	81,829
Bad debt expense	3,772	2,638	7,237	5,293
Acquisition and integration expenses	636	0	808	0
Restructuring expense	202	3,475	502	4,774
Amortization of intangibles	878	819	1,757	1,638
Income from operations	2,861	4,468	6,905	9,648
Interest expense, net	6,790	6,235	13,359	12,847
Income (loss) before income taxes	(3,929)	(1,767)	(6,454)	(3,199)
Income Tax Expense (Benefit)	364	(127)	(138)	(544)
Loss from continuing operations, net of income taxes	(4,293)	(1,640)	(6,316)	(2,655)
(Loss) income from discontinued operations, net of income taxes	76,059	(686)	75,379	3,270
Net income (loss)	$ 71,766	$ (2,326)	$ 69,063	$ 615
Income (loss) per common share
Basic loss from continuing operations	$ (0.07)	$ (0.03)	$ (0.11)	$ (0.05)
Basic (loss) income from discontinued operations	1.36	(0.01)	1.36	0.06
Basic	1.29	(0.04)	1.25	0.01
Diluted loss from continuing operations	(0.07)	(0.03)	(0.11)	(0.05)
Diluted (loss) income from discontinued operations	1.36	(0.01)	1.36	0.06
Diluted	$ 1.29	$ (0.04)	$ 1.25	$ 0.01
Weighted average common shares outstanding
Basic	55,746	54,298	55,143	54,216
Diluted	55,746	54,298	55,143	54,216

UNAUDITED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2012	Jun. 30, 2011
Cash flows from operating activities:
Net income (loss)	$ 69,063	$ 615
(Loss) income from discontinued operations, net of income taxes	75,379	3,270
Loss from continuing operations, net of income taxes	(6,316)	(2,655)
Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities:
Depreciation and amortization	3,981	2,980
Amortization of intangibles	1,757	1,638
Amortization of deferred financing costs	576	503
Change in deferred income tax	1,404	(167)
Compensation under stock-based compensation plans	2,711	2,252
Loss on disposal of fixed assets	45	64
Changes in assets and liabilities, net of acquired business:
Receivables, net of bad debt expense	78,925	(7,905)
Inventory	(3,104)	2,337
Prepaid expenses and other assets	4,769	(63)
Accounts payable	(50,313)	(803)
Claims payable	(860)	2,161
Amounts due to plan sponsors	462	4,062
Accrued expenses and other liabilities	8,797	5,144
Net cash provided by (used in) operating activities from continuing operations	42,834	9,548
Net cash provided by operating activities from discontinued operations	(21,195)	28,950
Net cash provided by operating activities	21,639	38,498
Cash flows from investing activities:
Purchases of property and equipment, net	(3,682)	(4,422)
Cash consideration paid for acquisitions, net of cash acquired	(466)	0
Cash consideration paid to DS Pharmacy	(2,935)	0
Cash consideration paid for unconsolidated joint ventures, net of cash acquired	(7,100)	0
Net cash used in investing activities from continuing operations	(14,183)	(4,422)
Net cash provided by (used in) investing activities from discontinued operations	161,499	(1,447)
Net cash used in investing activities	147,316	(5,869)
Cash flows from financing activities:
Borrowings on line of credit	848,633	841,200
Repayments on line of credit	(882,455)	(874,301)
Repayments of capital leases	(2,211)	(59)
Deferred and other financing costs	0	(22)
Net proceeds from exercise of employee stock compensation plans	5,675	691
Surrender of stock to satisfy minimum tax withholding	(174)	(138)
Net cash (used in) provided by financing activities	(30,532)	(32,629)
Net change in cash and cash equivalents	138,423	0
Cash and cash equivalents - end of period	0	0
Cash and cash equivalents - end of period	138,423	0
DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid during the period for interest	13,641	14,020
Cash paid during the period for income taxes, net of refunds	313	682
Capital lease obligations incurred to acquire property and equipment	$ 20	$ 0

BASIS OF PRESENTATION	6 Months Ended
BASIS OF PRESENTATION	Jun. 30, 2012
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Business Description and Basis of Presentation [Text Block]	BASIS OF PRESENTATION These Unaudited Consolidated Financial Statements should be read in conjunction with the Audited Consolidated Financial Statements, including the notes thereto, and other information included in the Annual Report on Form 10-K of BioScrip, Inc. and its wholly-owned subsidiaries (the “Company”) for the year ended December 31, 2011 (the “Form 10-K”) filed with the U.S. Securities and Exchange Commission. These Unaudited Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information, and the instructions to Form 10-Q and Article 10 of Regulation S-X promulgated under the Securities Exchange Act of 1934, as amended. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. The information furnished in these Unaudited Consolidated Financial Statements reflects all adjustments, including normal recurring adjustments, which are, in the opinion of management, necessary for a fair presentation of the results for the interim periods presented. Operating results for the three and six months ended June 30, 2012 are not necessarily indicative of the results that may be expected for the full year ended December 31, 2012. The accounting policies followed for interim financial reporting are similar to those disclosed in Note 2 of the Audited Consolidated Financial Statements included in the Form 10-K. The Unaudited Consolidated Financial Statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in the consolidation. In accordance with the applicable accounting guidance for the consolidation of variable interest entities, the Company analyzes its variable interests to determine if an entity in which it has a variable interest is a variable interest entity. The Company's analysis includes both quantitative and qualitative reviews. The Company bases its quantitative analysis on the forecasted cash flows of the entity, and its qualitative analysis on its review of the design of the entity, its organizational structure, including decision-making ability, and relevant financial agreements. The Company also uses its qualitative analysis to determine if it must consolidate a variable interest entity as its primary beneficiary. The Company has an affiliate equity investment in a variable interest entity that has developed a platform that facilitates the flow, management and sharing of vital health and medical information with stakeholders across the healthcare ecosystem. The Company concluded that the entity is a variable interest entity because the equity investment at risk is not sufficient to permit the entity to finance its activities without additional support from other parties. The Company has determined that it is not the primary beneficiary as power to direct the activities that most significantly impact economic performance of the entity is held by another stakeholder, and therefore does not consolidate the entity. The Company recorded its net investment in the variable interest entity of $6.9 million in the investments in and advances to unconsolidated affiliate line on the accompanying Consolidated Balance Sheets. The Company cannot quantify its maximum exposure to loss as a result of its involvement with the variable interest entity. As a result of the Company entering into a purchase agreement on February 1, 2012 with respect to the sale of its traditional and specialty pharmacy mail operations and community retail pharmacy stores (see Note 2), the Company reevaluated its segments in accordance with the provisions of Accounting Standards Codification (“ASC”) Topic 280, Segment Reporting (“ASC 280”). Based on its review, the Company changed its operating and reportable segments from “Infusion/Home Health Services” and “Pharmacy Services” to its new operating and reportable segments: “Infusion Services", "Home Health Services” and “PBM Services”. These three new operating and reportable segments reflect how the Company's chief operating decision maker reviews the Company's results in terms of allocating resources and assessing performance. As a result, prior period disclosures reflect the change in operating and reportable segments. Refer to Note 9 for more information. Certain prior period amounts have been reclassified to conform to the current year presentation. Such reclassifications have no material effect on the Company's previously reported consolidated financial position, results of operations or cash flow. The Company has evaluated events that occurred during the period subsequent to the balance sheet date through the filing date of this Form 10-Q. Refer to Note 13 for more information.

DISCONTINUED OPERATIONS

6 Months Ended

Jun. 30, 2012

DISCONTINUED OPERATIONS [Abstract]

Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]

DISCONTINUED OPERATIONS

On February 1, 2012, the Company entered into a Community Pharmacy and Mail Business Purchase Agreement (the “Asset Purchase Agreement”) by and among Walgreen Co. and certain subsidiaries (collectively, the "Buyers") and the Company and certain subsidiaries (collectively, the "Sellers") with respect to the sale of certain assets, rights and properties (the “Pharmacy Services Asset Sale”) relating to the Sellers' traditional and specialty pharmacy mail operations and community retail pharmacy stores.

On May 4, 2012, pursuant to the terms of the Asset Purchase Agreement, the Company received approximately $158.8 million at closing, including the value of inventories on hand attributable to the operations subject to the Pharmacy Services Asset Sale. Based on events related directly or indirectly to the Buyers' retention of certain business after the closing, the Company has also received approximately $740,000 and may receive up to an additional $15.0 million in additional purchase price, within the 24 month period following the closing, or be required to refund up to approximately $6.4 million of purchase price to the Buyers, within the 14 month period following the closing. The purchase price excluded all accounts receivable and working capital liabilities relating to the operations subject to the Pharmacy Services Asset Sale, which were retained by the Company. Approximately $32.4 million of these net assets remained at June 30, 2012, and the Company anticipates the collection of these balances during the remainder of the year.

As a result of the Pharmacy Services Asset Sale, the Company recognized a pretax gain of $100.0 million, including transaction costs of $5.6 million, during the three months ended June 30, 2012. The Company also recognized approximately $13.0 million of impairment costs, employee severance and other benefit-related costs, facility-related costs, and other one-time charges as a result of the transaction in the three months ended June 30, 2012, resulting in a net effect of approximately $87.0 million. See Note 6 - Property and Equipment, for further information on the impairment. The impairment costs, employee severance and other benefit-related costs, facility-related costs, and other one-time charges are included in income (loss) from discontinued operations, net of income taxes on the Unaudited Consolidated Statements of Operations. As of June 30, 2012, there are accruals of $2.8 million related to these costs in accrued expenses and other current liabilities and other non-current liabilities on the Unaudited Consolidated Balance Sheets. The accrual activity consisted of the following (in thousands):



	Impairment Costs			Employee Severance and Other Benefits			Facility-Related Costs		Other Costs			Total
Liability balance as of December 31, 2011	$	—		$	—		$	—	$	—		$	—
Expenses	5,839			5,349			1,071		773			13,032
Cash payments	—			(3,885		)	—		(2,579		)	(6,464		)
Non-cash charges	$	(5,839	)	$	—		$	—	$	2,024		$	(3,815	)
Liability balance as of June 30, 2012	$	—		$	1,464		$	1,071	$	218		$	2,753

In addition, the Company and its subsidiaries and certain subsidiaries of the Buyers entered into an agreement concurrently with the Asset Purchase Agreement which provided that BioScrip ceased to be the sole fulfillment pharmacy for customers who came through the drugstore.com website. The agreement provided for a cash payment of $3.0 million to the Company and the payment of $2.9 million to the Buyers related to contingent consideration from the Company's 2010 acquisition of the prescription pharmacy business of DS Pharmacy, both of which occurred during the three months ended March 31, 2012.

The transaction included the sale of 27 community pharmacy locations and certain assets of three community pharmacy locations and three traditional and specialty mail service operations, which constituted all of the Company's operations in the community pharmacy and mail order lines of business. Two mail order locations which were not transferred as part of the Pharmacy Services Asset Sale have started providing infusion pharmacy services. The Company is evaluating whether to convert some of the community pharmacy locations not sold to provide infusion pharmacy services. The assets of the components of the businesses being transferred are included in discontinued operations on the accompanying Consolidated Balance Sheets. On May 4, 2012, the carrying value of the assets included in the Pharmacy Services Asset Sale was as follows (in thousands):



Inventory	$	30,560
Prepaid expenses and other current assets	299
Total current assets	30,859
Property and equipment, net	1,592
Goodwill	11,754
Intangible assets, net	2,503
Total assets	$	46,708

During the three months ended June 30, 2012, as a result of the divestiture process, the Company's management commenced an assessment of the Company's continuing operations in order to align its corporate structure with its remaining operations. As part of these efforts, the Company may incur significant charges such as the write down of certain long−lived assets, employee severance, other restructuring type charges, temporary redundant expenses, potential cash bonus payments and potential accelerated payments or terminated costs for certain of its contractual obligations, which may impact the Company's future Consolidated Financial Statements.

The operating results of the traditional and specialty pharmacy mail operations and community pharmacies for the three and six months ended June 30, 2012 and 2011 are summarized below. These results include costs directly attributable to the components of the businesses which were divested. In addition, interest expense of $0.2 million and $1.0 million for the three months ended and $0.9 million and $1.6 million for the six months ended June 30, 2012 and 2011, respectively, has been allocated to discontinued operations on the basis of the borrowing base that will be reduced as a result of the Pharmacy Services Asset Sale and the working capital associated with the business which will be reduced. Income tax expense of $5.1 million and income tax benefit of $0.2 million for the three months ended and income tax expense of $5.1 million and $0.4 million for the six months ended June 30, 2012 and 2011, respectively, has also been allocated to discontinued operations. These adjustments have been made for all periods presented. Depreciation expense was no longer incurred on fixed assets included in the disposal group as of February 1, 2012, the date the Company entered into the Asset Purchase Agreement.



Discontinued Operations Results
(in thousands)

	Three Months Ended June 30,						Six Months Ended June 30,
	2012			2011			2012			2011

Revenue	$	128,436		$	309,829		$	466,539		$	618,289

Gross profit	$	7,078		$	24,388		$	30,038		$	50,300

Gross profit as a percentage of revenue	5.5		%	7.9		%	6.4		%	8.1		%

Gain on sale, before income taxes	$	100,012		$	—		$	100,012		$	—

Impairment costs, employee severance and other benefit-related costs, and other one-time charges	$	(13,032	)	$	—		$	(13,032	)	$	—

(Loss) income from discontinued operations, net of income taxes	$	76,059		$	(686	)	$	75,379		$	3,270

- Definition

The entire disclosure for the facts and circumstances leading to the completed or expected disposal, manner and timing of disposal, the gain (loss) recognized in the income statement and the income statement caption that includes that gain (loss), amounts of revenues and pretax profit or loss reported in discontinued operations, the segment in which the disposal group was reported, and the classification (whether sold or classified as held for sale) and carrying value of the assets and liabilities comprising the disposal group. Includes all disposal groups, including those classified as components of the entity (discontinued operations).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 144
-Paragraph 43-48
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6391110&loc=d3e2941-110230

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1361-107760

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1510-107760

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6892542&loc=d3e1020-107759

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6892542&loc=d3e1012-107759

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6892542&loc=d3e957-107759

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1474-107760

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6390789&loc=d3e2443-110228

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1436-107760

+ Details

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

6 Months Ended

Jun. 30, 2012

Accounting Policies [Abstract]

Significant Accounting Policies [Text Block]

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Income (Loss) Per Share

The following table sets forth the computation of basic and diluted income (loss) per common share (in thousands, except for per share amounts):



	Three Months Ended June 30,						Six Months Ended June 30,
	2012			2011			2012			2011
Numerator:
Loss from continuing operations, net of income taxes	$	(4,293	)	$	(1,640	)	$	(6,316	)	$	(2,655	)
(Loss) income from discontinued operations, net of income taxes	76,059			(686		)	75,379			3,270
Net income (loss)	$	71,766		$	(2,326	)	$	69,063		$	615

Denominator - Basic:
Weighted average number of common shares outstanding	55,746			54,298			55,143			54,216

Basic loss from continuing operations	$	(0.07	)	$	(0.03	)	$	(0.11	)	$	(0.05	)
Basic (loss) income from discontinued operations	1.36			(0.01		)	1.36			0.06
Basic (loss) income	$	1.29		$	(0.04	)	$	1.25		$	0.01

Denominator - Diluted:
Weighted average number of common shares outstanding	55,746			54,298			55,143			54,216
Common share equivalents of outstanding stock options and restricted awards	—			—			—			—
Total diluted shares outstanding	55,746			54,298			55,143			54,216

Diluted loss from continuing operations	$	(0.07	)	$	(0.03	)	$	(0.11	)	$	(0.05	)
Diluted income (loss) from discontinued operations	1.36			(0.01		)	1.36			0.06
Diluted income (loss)	$	1.29		$	(0.04	)	$	1.25		$	0.01

The computation of diluted shares for the three and six months ended June 30, 2012 and 2011 excludes the effect of 3.4 million warrants with an exercise price of $10 issued in connection with the acquisition of Critical Homecare Solutions Holdings, Inc. ("CHS") in 2010. In addition to the warrants, the computation of diluted shares for the three months ended June 30, 2012 and 2011 excludes the effect of 5.6 million and 6.9 million, respectively, of other common stock equivalents as their inclusion would be anti-dilutive. The computation of diluted shares for the six months ended June 30, 2012 and 2011 excludes the effect of 5.6 million and 6.9 million, respectively, of other common stock equivalents as their inclusion would be anti-dilutive.

Recent Accounting Pronouncements

In September 2011, the Financial Accounting Standards Board ("FASB") issued ASU 2011-08, Testing Goodwill for Impairment (“ASU 2011-08”). ASU 2011-08 allows an entity to first assess qualitative factors to determine whether it is necessary to perform the two-step quantitative goodwill impairment test. Under these amendments, an entity would not be required to calculate the fair value of a reporting unit unless the entity determines, based on a qualitative assessment, that it is more likely than not that its fair value is less than its carrying amount. The amendments include a number of events and circumstances for an entity to consider in conducting the qualitative assessment. The Company adopted ASU 2011-08 on January 1, 2012. The adoption of this statement did not have a material effect on the Company's Unaudited Consolidated Financial Statements.

In May 2011, the FASB issued ASU 2011-04, Amendments to Achieve Common Fair Value Measurement and Disclosure Requirements in U.S. GAAP and IFRS (“ASU 2011-04”). ASU 2011-04 generally aligns the principles for fair value measurements and the related disclosure requirements under U.S. GAAP and International Financial Reporting Standards. From a U.S. GAAP perspective, the amendments are largely clarifications, but some could have a significant effect on certain companies. A number of new disclosures also are required. Except for certain disclosures, the guidance applies to public and nonpublic companies and is to be applied prospectively. The Company adopted ASU 2011-04 on January 1, 2012. The adoption of this statement is not expected to have a material effect on the Company's Unaudited Consolidated Financial Statements.

GOODWILL AND INTANGIBLE ASSETS

6 Months Ended

Jun. 30, 2012

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill and Intangible Assets Disclosure [Text Block]

GOODWILL AND INTANGIBLE ASSETS

As a result of the Company entering into the Asset Purchase Agreement with respect to the Pharmacy Services Asset Sale, the Company reevaluated its operating and reportable segments. Based on its review, the Company changed its operating and reportable segments from “Infusion/Home Health Services” and “Pharmacy Services” to its new operating and reportable segments: “Infusion Services", "Home Health Services” and “PBM Services”. The Company has assigned goodwill to the new segments based on relative fair market value of the segment assets as measured by discounted future cash flows .

Goodwill consisted of the following as of June 30, 2012 and December 31, 2011 (in thousands):



	June 30, 2012		December 31, 2011
Infusion	$	265,859	$	265,859
Home Health Services	33,784		33,784
PBM Services	12,744		12,744
Total	$	312,387	$	312,387

Intangible assets consisted of the following as of June 30, 2012 and December 31, 2011 (in thousands):



		June 30, 2012
	Estimated Useful Life	Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount
Indefinite Lived Assets
Certificates of need	indefinite	$	9,600	$	—		$	9,600
Nursing trademarks	indefinite	5,800		—			5,800
		15,400		—			15,400
Definite Lived Assets
Customer list	6 - 16 months	512		(219		)	293
Infusion trademarks	3 years	2,600		(1,973		)	627
Infusion customer relationships	3 years	7,200		(5,462		)	1,738
		10,312		(7,654		)	2,658
		$	25,712	$	(7,654	)	$	18,058



		December 31, 2011
	Estimated Useful Life	Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount
Indefinite Lived Assets
Certificates of need	indefinite	$	9,600	$	—		$	9,600
Nursing trademarks	indefinite	5,800		—			5,800
		15,400		—			15,400
Definite Lived Assets
Customer list	6 months	319		(101		)	218
Infusion trademarks	3 years	2,600		(1,538		)	1,062
Infusion customer relationships	3 years	7,200		(4,258		)	2,942
		10,119		(5,897		)	4,222
		$	25,519	$	(5,897	)	$	19,622

The Company had $5.6 million of intangible assets related to customer lists, a transitional services contract and license and marketing related intangibles included within the non-current assets from discontinued operations line on the accompanying Consolidated Balance Sheet as of December 31, 2011.

Total amortization of intangible assets was $0.9 million and $0.8 million for the three months ended June 30, 2012 and 2011, respectively. Total amortization of intangible assets was $1.8 million and $1.6 million for the six months ended June 30, 2012 and 2011, respectively. Amortization expense is expected to be the following (in thousands):



2012 (six months)	$	1,822
2013	836
Total	$	2,658

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References + Details

RESTRUCTURING EXPENSE

6 Months Ended

Jun. 30, 2012

Restructuring and Related Activities [Abstract]

Restructuring and Related Activities Disclosure [Text Block]

RESTRUCTURING EXPENSE

In the fourth quarter of 2010, the Company commenced a strategic assessment of its business and operations ("Restructuring Phase I"). This assessment focused on expanding revenue opportunities and lowering corporate overhead, including workforce and benefit reductions and facility rationalization. In addition to addressing corporate overhead, the strategic assessment examined the Company's market strengths and opportunities and compared the Company's position to that of its competitors. As a result of the assessment, the Company focused its growth on investments in the Infusion and Home Health Services segments and elected to pursue offers for its traditional and specialty pharmacy mail operations and community retail pharmacy stores. Accordingly, the Company consummated the Pharmacy Services Asset Sale relating to its traditional and specialty pharmacy mail operations and community retail pharmacy stores.

During the three months ended June 30, 2012, as a result of the divestiture process, the Company's management team commenced an assessment of the Company's continuing operations in order to align its corporate structure with its remaining operations ("Restructuring Phase II"). As part of these efforts, the Company may incur significant charges such as the write down of certain long−lived assets, employee severance, other restructuring type charges, temporary redundant expenses, potential cash bonus payments and potential accelerated payments or termination costs for certain of its contractual obligations, which may impact the Company's future Consolidated Financial Statements.

Restructuring Phase I

As a result of Restructuring Phase I, the Company incurred restructuring expenses of approximately $3.5 million during the three months ended June 30, 2011, and $0.3 million and $4.8 million during the six months ended June 30, 2012 and 2011, respectively. The Company did not incur restructuring expense related to Phase I during the three months ended June 30, 2012. Restructuring expenses during the three months ended June 30, 2011 consisted of approximately $1.7 million of third-party consulting costs, $1.2 million of employee severance and other benefit-related costs related to workforce reductions and $0.6 million of other costs, such as lease termination costs. Restructuring expenses during the six months ended June 30, 2012 consisted of approximately $0.3 million of third-party consulting costs. Restructuring expenses during the six months ended June 30, 2011 consisted of approximately $2.7 million of third-party consulting costs, $1.5 million of employee severance and other benefit-related costs related to workforce reductions and $0.6 million of other costs.

Since inception of the strategic assessment and related restructuring plan, the Company has incurred approximately $10.2 million in total expenses, consisting of $4.4 million of third-party consulting costs, $4.2 million of employee severance and other benefit-related costs related to workforce reductions and $1.6 million of facility-related costs.

The restructuring costs are included in restructuring expense on the Unaudited Consolidated Statements of Operations and, along with other temporary redundant expenses and termination costs, as part of the calculation of Segment Adjusted EBITDA, as defined in Note 9. As of June 30, 2012, there are restructuring accruals of $2.3 million related to Phase I included in accrued expenses and other current liabilities and other non-current liabilities on the Unaudited Consolidated Balance Sheets. The restructuring accrual activity consisted of the following (in thousands):



	Employee Severance and Other Benefits			Consulting Costs			Facility-Related Costs			Other Costs		Total
Liability balance as of December 31, 2011	$	2,109		$	50		$	1,289		$	—	$	3,448
Expenses	—			300			—			—		300
Cash payments	(1,234		)	(40		)	(223		)	—		(1,497		)
Liability balance as of June 30, 2012	$	875		$	310		$	1,066		$	—	$	2,251

Restructuring Phase II

As a result of Restructuring Phase II, the Company incurred restructuring expenses of approximately $0.2 million during the three and six months ended June 30, 2012. The Company did not incur restructuring expense related to Phase II during 2011. Restructuring expenses during the three and six months ended June 30, 2012 consisted of approximately $0.2 million of employee severance and other benefit-related costs related to workforce reductions.

Since inception of the strategic assessment and related restructuring plan, the Company has incurred approximately $0.2 million in total expenses, consisting of $0.2 million of employee severance and other benefit-related costs related to workforce reductions.

The restructuring costs are included in restructuring expense on the Unaudited Consolidated Statements of Operations and, along with other temporary redundant expenses and termination costs, as part of the calculation of Segment Adjusted EBITDA, as defined in Note 9. As of June 30, 2012, there are restructuring accruals of $0.2 million related to Phase II included in accrued expenses and other current liabilities and other non-current liabilities on the Unaudited Consolidated Balance Sheets. The restructuring accrual activity consisted of the following (in thousands):



	Employee Severance and Other Benefits			Consulting Costs		Facility-Related Costs		Other Costs		Total
Liability balance as of December 31, 2011	$	—		$	—	$	—	$	—	$	—
Expenses	202			—		—		—		202
Cash payments	(7		)	—		—		—		(7		)
Liability balance as of June 30, 2012	$	195		$	—	$	—	$	—	$	195

- Definition

The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.

+ References + Details

PROPERTY AND EQUIPMENT

6 Months Ended

Jun. 30, 2012

Property, Plant and Equipment [Abstract]

Property, Plant and Equipment Disclosure [Text Block]

PROPERTY AND EQUIPMENT

Property and equipment consisted of the following (in thousands):



	June 30, 2012			December 31, 2011
Computer and office equipment, including equipment acquired under capital leases	$	13,653		$	15,684
Software capitalized for internal use	9,587			15,520
Vehicles, including equipment acquired under capital leases	1,725			1,701
Medical equipment	14,832			14,698
Work in progress	1,240			2,813
Furniture and fixtures	3,102			3,626
Leasehold improvements	7,226			6,507
	51,365			60,549
Less: Accumulated depreciation	(30,508		)	(33,598		)
Property and equipment, net	$	20,857		$	26,951

The Company had an insignificant amount of vehicles under capital lease as of June 30, 2012 and December 31, 2011.

Depreciation Expense

Depreciation expense, including expense related to assets under capital lease, for the three months ended June 30, 2012 and 2011 was $2.1 million and $1.6 million, respectively. Depreciation expense, including expense related to assets under capital lease, for the six months ended June 30, 2012 and 2011 was $4.0 million and $3.0 million, respectively. Depreciation expense for the three months ended June 30, 2012 and 2011 included $0.5 million and $0.7 million, respectively, for costs related to software capitalized for internal use. Depreciation expense for the six months ended June 30, 2012 and 2011 included $1.2 million and $1.3 million, respectively, for costs related to software capitalized for internal use.

Impairment

The Company assesses the impairment of its assets whenever events or changes in circumstances indicate that the carrying value may not be recoverable. As a result of the Pharmacy Services Asset Sale (see Note 2 - Discontinued Operations), the Company evaluated certain facilities that were retained by the Company following the divestiture of our generics business.

As a result of the evaluation, the Company determined that a triggering event occurred during the three months ended June 30, 2012, giving rise to the need to assess the recoverability of certain of our assets previously used in the specialty pharmacy mail operations and community retail pharmacy operations, which consisted primarily of software capitalized for internal use, leasehold improvements and work in progress. Based on our analysis, we recorded a $5.8 million impairment charge in income (loss) from discontinued operations, net of income taxes.

- Definition

The entire disclosure for long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software. This disclosure may include property plant and equipment accounting policies and methodology, a schedule of property, plant and equipment gross, additions, deletions, transfers and other changes, depreciation, depletion and amortization expense, net, accumulated depreciation, depletion and amortization expense and useful lives, income statement disclosures, assets held for sale and public utility disclosures.

+ References + Details

DEBT

6 Months Ended

Jun. 30, 2012

Debt Disclosure [Abstract]

Debt Disclosure [Text Block]

DEBT

As of June 30, 2012 the Company’s long-term debt consisted of the following obligations (in thousands):



Revolving credit facility	$	30,000
Senior unsecured notes	225,000
Capital leases	2,446
	257,446
Less - obligations maturing within one year	31,230
Long term debt - net of current portion	$	226,216

As of June 30, 2012, the carrying amount of the Company's senior unsecured notes was $225.0 million, and the estimate of the fair value of the senior unsecured notes, based on current market rates for debt of the same risk and maturities, was $259.7 million. The estimated fair value was calculated using level 3 inputs and was based on current market rates for debt of the same risk and maturities.

As of June 30, 2012, borrowings under the Company's senior secured revolving credit facility include debt having variable interest rates totaling $30.0 million. The Company believes the carrying value of the debt under the senior secured revolving credit facility approximates fair market value.

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References + Details

COMMITMENTS AND CONTINGENCIES

6 Months Ended

Jun. 30, 2012

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies Disclosure [Text Block]

COMMITMENTS AND CONTINGENCIES

Legal Proceedings

On June 30, 2009, Professional Home Care Services, Inc., or PHCS, one of the subsidiaries the Company acquired through its acquisition of CHS, was sued by Alexander Infusion, LLC, a New York-based home infusion company, in the Supreme Court of the State of New York. The complaint alleges principally breach of contract arising in connection with PHCS's failure to consummate an acquisition of Alexander Infusion after failing to satisfy the conditions to PHCS's obligation to close. Alexander Infusion has sued for $3.5 million in damages. The Company believes Alexander Infusion's claims to be without merit and intends to continue to defend against the allegations vigorously. Furthermore, under the merger agreement, subject to certain limits, the former CHS stockholders agreed to indemnify the Company in connection with any losses arising from claims made in respect of the acquisition agreement entered into between PHCS and Alexander Infusion. As of June 30, 2012, no liability or indemnification reimbursement has been accrued in the Unaudited Consolidated Financial Statements as a loss is not considered probable.

Government Regulation

Various Federal and state laws and regulations affecting the healthcare industry do or may impact the Company's current and planned operations, including, without limitation, Federal and state laws prohibiting kickbacks in government health programs, Federal and state antitrust and drug distribution laws, and a wide variety of consumer protection, insurance and other state laws and regulations. Management strives to maintain the Company in substantial compliance with all existing laws and regulations material to the operation of its business. However, such laws and regulations are subject to rapid change and often are uncertain in their application. As controversies continue to arise in the healthcare industry (for example, the efforts of Plan Sponsors and pharmacy benefit managers to limit formularies, alter drug choice and establish limited networks of participating pharmacies), Federal and state regulation and enforcement priorities in this area can be expected to increase, the impact of which on the Company cannot be predicted.

From time to time, the Company responds to subpoenas and requests for information from governmental agencies. The Company cannot predict with certainty what the outcome of any of the foregoing might be. There can be no assurance that the Company will not be subject to scrutiny or challenge under one or more existing laws or that any such challenge would not be successful. Any such challenge, whether or not successful, could have a material effect upon the Company's Consolidated Financial Statements. A violation of the Federal anti-kickback statute, for example, may result in substantial criminal penalties, as well as suspension or exclusion from the Medicare and Medicaid programs. Moreover, the costs and expenses associated with defending these actions, even where successful, can be significant. Further, there can be no assurance the Company will be able to maintain any of the regulatory approvals that may be required to operate its business, and the failure to do so could have a material effect on the Company's Unaudited Consolidated Financial Statements.

Legal Settlements

Following responses to government subpoenas and discussions with the government, in May 2011, the Company was advised of a qui tam lawsuit filed under seal in federal court in Minnesota in 2006 and naming the Company as defendant. The complaint alleged violations of healthcare statutes and regulations by the Company and predecessor companies dating back to 2000. The Company has negotiated a settlement with the Minneapolis office of the United States Attorney, which is part of the US Department of Justice (“DOJ”), resolving the financial aspects of these claims. In connection with such settlement, the Company has committed to resolve the interests of certain State governments in this matter, in exchange for a payment by the Company of a maximum amount, which was negotiated between the DOJ and State governments. The additional claims of the qui tam relator and counsel remain to be resolved by the Company through negotiation or litigation. During the year ended December 31, 2011, the Company recorded a legal settlement expense of $4.8 million related to the proposed settlement with the DOJ and State governments. During the three months ended June 30, 2012, the Company recorded an additional legal settlement expense of $0.3 million to account for the final settlement amount. The legal settlement expenses were included in income (loss) from discontinued operations, net of income taxes in the accompanying Unaudited Consolidated Statements of Operations. As of June 30, 2012 and December 31, 2011, there was a liability of $5.1 million and $4.8 million, respectively, included in accrued expenses and other current liabilities in the accompanying Consolidated Balance Sheets related to the settlement.

PBM Services Payment Delay

A large PBM Services customer has become approximately two months behind payment terms as of June 30, 2012. The total amount owed to the Company is $6.8 million. In an effort to resolve this matter, which is an ongoing effort, the Company has required that this customer provide written assurance to both the Company and the Company's network pharmacies that this customer will become current by the end of August, 2012. As of June 30, 2012, no liability has been accrued in the Unaudited Consolidated Financial Statements as a loss is not considered probable.

Leases

The Company leases its facilities and certain equipment under various operating leases with third parties. The majority of these leases contain escalation clauses that increase base rent payments based upon either the Consumer Price Index or an agreed upon schedule.

In addition, the Company utilizes capital leases agreements with third parties to obtain certain assets such as vehicles. Interest rates on capital leases are both fixed and variable and range from 3% to 7%.

As of June 30, 2012, future minimum lease payments, including interest, under operating and capital leases are as follows (in thousands):



	Operating Leases		Capital Leases		Total
2012 (six months)	$	3,060	$	1,160	$	4,220
2013	4,620		1,038		5,658
2014	3,307		198		3,505
2015	2,686		165		2,851
2016	2,188		3		2,191
2017 and thereafter	3,770		—		3,770
Total	$	19,631	$	2,564	$	22,195

Rent expense for leased facilities and equipment was approximately$1.4 million and $1.4 million for the three months ended June 30, 2012 and 2011, respectively. Rent expense for leased facilities and equipment was approximately $2.9 million and $2.8 million for the six months ended June 30, 2012 and 2011, respectively.

Purchase Commitments

As of June 30, 2012, the Company had commitments to purchase prescription drugs from drug manufacturers of approximately $13.5 million during the remainder of 2012. These purchase commitments are made at levels expected to be used in the normal course of business.

- Definition

The entire disclosure for commitments and contingencies.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Interpretation (FIN)
-Number 14
-Paragraph 3
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 5
-Paragraph 9, 10, 11, 12
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.25)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6952336&loc=d3e14435-108349

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 460
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=6398077&loc=d3e12565-110249

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 440
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6394976&loc=d3e25287-109308

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621

+ Details

OPERATING AND REPORTABLE SEGMENTS

6 Months Ended

Jun. 30, 2012

Segment Reporting [Abstract]

Segment Reporting Disclosure [Text Block]

OPERATING AND REPORTABLE SEGMENTS

As a result of the Company entering into a purchase agreement on February 1, 2012 with respect to the sale of its traditional and specialty pharmacy mail operations and community retail pharmacy stores, the Company reevaluated its operating and reportable segments in accordance with the provisions of Accounting Standards Codification (“ASC”) Topic 280, Segment Reporting (“ASC 280”). Based on its review, the Company changed its operating and reportable segments from “Infusion/Home Health Services” and “Pharmacy Services” to its new operating and reportable segments: “Infusion Services", "Home Health Services” and “PBM Services”. These three new operating and reportable segments reflect how the Company's chief operating decision maker reviews the Company's results in terms of allocating resources and assessing performance. Prior period disclosures reflect the change in reportable segments.

The Infusion Services operating and reportable segment provides services consisting of home infusion therapy, respiratory therapy and the provision of durable medical equipment, products and services. Infusion services include the dispensing and administering of infusion-based drugs, which typically require additional nursing and clinical management services, equipment to administer the correct dosage and patient training designed to improve patient outcomes. Home infusion services also include the dispensing of self-injectable therapies.

The Home Health Services operating and reportable segment provides services including the provision of skilled nursing services and therapy visits, private duty nursing services, hospice services, rehabilitation services and medical social services to patients primarily in their home.

The PBM Services operating and reportable segment consists of integrated pharmacy benefit management ("PBM") services, which primarily consists of discount cash card programs. The discount cash card programs provide a cost effective alternative for individuals who may be uninsured, underinsured or may have restrictive coverage that disallows reimbursement for certain medications. Under these discount programs, individuals who present a discount card at one of the Company's participating network pharmacies or who order medications through one of the Company's participating mail service pharmacies receive prescription medications at a discounted price compared to the retail or "cash" price. In addition, in the Company's capacity as a pharmacy benefit manager, it has fully funded prescription benefit programs where the Company reimburses its network pharmacies and third party payors in turn reimburse the Company based on Medi-Span reported pricing for those claims fulfilled for their plan participants.

The Company's chief operating decision maker evaluates segment performance and allocates resources based on Segment Adjusted EBITDA. Segment Adjusted EBITDA is defined as income (loss) from continuing operations, net of income taxes adjusted for net interest expense, income tax expense (benefit), depreciation, amortization of intangibles and stock-based compensation expense and prior to the allocation of certain corporate expenses. Segment Adjusted EBITDA excludes acquisition, integration, severance and other employee costs; restructuring expense; and other expenses related to the Company's strategic assessment. Segment Adjusted EBITDA is a measure of earnings that management monitors as an important indicator of operating and financial performance. The accounting policies of the operating and reportable segments are consistent with those described in the Company's summary of significant accounting policies.

Segment Reporting Information

(in thousands)



	Three Months Ended June 30,						Six Months Ended June 30,
	2012			2011			2012			2011
Results of Operations:
Revenue:
Infusion Services - product revenue	$	108,557		$	87,717		$	215,360		$	177,499
Infusion Services - service revenue	2,416			2,136			4,667			4,079
Total Infusion Services revenue	110,973			89,853			220,027			181,578

Home Health Services - service revenue	16,860			17,673			33,571			34,881

PBM Services - service revenue	28,068			24,049			57,936			45,953

Total revenue	$	155,901		$	131,575		$	311,534		$	262,412

Adjusted EBITDA by Segment before corporate overhead:
Infusion Services	$	8,026		$	8,340		$	15,809		$	17,624
Home Health Services	1,075			1,787			2,155			2,793
PBM Services	6,364			6,764			12,462			12,887
Total Segment Adjusted EBITDA	15,465			16,891			30,426			33,304

Corporate overhead	(6,458		)	(5,362		)	(13,040		)	(12,012		)

Interest expense, net	(6,790		)	(6,235		)	(13,359		)	(12,847		)
Income tax (expense) benefit	(364		)	127			138			544
Depreciation	(2,050		)	(1,647		)	(3,981		)	(2,980		)
Amortization of intangibles	(878		)	(819		)	(1,757		)	(1,638		)
Stock-based compensation expense	(1,745		)	(1,120		)	(2,711		)	(2,252		)
Acquisition, integration, severance and other employee costs	(1,271		)	—			(1,530		)	—
Restructuring expense	(202		)	(3,475		)	(502		)	(4,774		)
Loss from continuing operations, net of income taxes	$	(4,293	)	$	(1,640	)	$	(6,316	)	$	(2,655	)

Supplemental Operating Data
							June 30, 2012			December 31, 2011
Total Assets
Infusion Services							$	366,198		$	353,999
Home Health Services							66,557			64,672
PBM Services							39,756			40,418
Corporate unallocated, including cash and cash equivalents							169,996			22,615
Assets from discontinued operations							—			59,005
Assets associated with discontinued operations, not sold							32,411			136,393
Total							$	674,918		$	677,102

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 131
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8981-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 35
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8984-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9054-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9031-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8924-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8538-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8906-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9038-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8864-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 33
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8971-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8844-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8380-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8595-108599

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8933-108599

+ Details

CONCENTRATION OF RISK	6 Months Ended
CONCENTRATION OF RISK	Jun. 30, 2012
Risks and Uncertainties [Abstract]
Concentration Risk Disclosure [Text Block]	CONCENTRATION OF RISK Customer and Credit Risk The Company provides trade credit to its customers in the normal course of business. One payor accounted for approximately 18% and 19% of revenue during the three months ended June 30, 2012 and 2011, respectively, and approximately 17% and 18% of revenue during the six months ended June 30, 2012 and 2011, respectively. The majority of the revenue is related to the Infusion Services segment. Therapy Revenue Risk The Company sells products related to the Immune Globulin (IVIG) therapy, which represented 20% and 26% of revenue during the three months ended June 30, 2012 and 2011, respectively and 21% and 26% of revenue during the six months ended June 30, 2012 and 2011, respectively. The revenue is related to the Infusion Services segment.

- Definition

The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 15A
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Statement of Position (SOP)
-Number 94-6
-Paragraph 21, 22, 24
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 21
-URI http://asc.fasb.org/extlink&oid=6947722&loc=d3e13537-108611

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6327-108592

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=6947722&loc=d3e13531-108611

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 18
-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6351-108592

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6404-108592

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 21
-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6442-108592

+ Details

INCOME TAXES

6 Months Ended

Jun. 30, 2012

Income Tax Disclosure [Abstract]

Income Tax Disclosure [Text Block]

INCOME TAXES

The Company’s Federal and state income tax benefit from continuing operations is summarized in the following table (in thousands):



	Three Months Ended June 30,						Six Months Ended June 30,
	2012			2011			2012			2011
Current
Federal	$	(120	)	$	(28	)	$	(149	)	$	(273	)
State	184			(6		)	11			(128		)
Total Current	64			(34		)	(138		)	(401		)
Deferred
Federal	262			(81		)	—			(125		)
State	38			(12		)	—			(18		)
Total deferred	300			(93		)	—			(143		)
Total income tax expense (benefit)	$	364		$	(127	)	$	(138	)	$	(544	)

The Company’s reconciliation of the statutory rate from continuing operations to the effective income tax rate is as follows for the three and six months ended June 30, 2012 and 2011 (in thousands):



	Three Months Ended June 30,						Six Months Ended June 30,
	2012			2011			2012			2011
Tax benefit at statutory rate	$	(1,375	)	$	(619	)	$	(2,258	)	$	(1,120	)
State tax benefit, net of Federal taxes	(223		)	(92		)	(364		)	(165		)
Change in tax contingencies	5			8			11			13
Valuation allowance changes affecting income tax expense	2,353			514			2,949			607
Other	(396		)	62			(476		)	121
Income tax expense (benefit)	$	364		$	(127	)	$	(138	)	$	(544	)

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph h
-Article 4

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 109
-Paragraph 136, 172
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 109
-Paragraph 43, 44, 45, 46, 47, 48, 49
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32718-109319

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(h))
-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32537-109319

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32559-109319

+ Details

STOCK-BASED COMPENSATION	6 Months Ended
STOCK-BASED COMPENSATION	Jun. 30, 2012
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	STOCK-BASED COMPENSATION BioScrip Equity Incentive Plans Under the Company's Amended and Restated 2008 Equity Incentive Plan (as amended and restated, the “2008 Plan”), the Company may issue, among other things, incentive stock options (“ISOs”), non-qualified stock options (“NQSOs”), stock appreciation rights ("SARs"), restricted stock, performance shares and performance units to employees and directors. While SARS are authorized under the 2008 Plan, they may also be issued outside of the plan. Under the 2008 Plan, 3,580,000 shares were originally authorized for issuance (subject to adjustment for grants made under the Company's 2001 Incentive Stock Plan (the “2001 Plan”) after January 1, 2008, as well as for forfeitures, expirations or awards that under the 2001 Plan otherwise settled in cash after the adoption thereof). Upon the effective date of the 2008 Plan, the Company ceased making grants under the 2001 Plan. The 2008 Plan is administered by the Company's Management Development and Compensation Committee (the “Compensation Committee”), a standing committee of the Board of Directors. On June 10, 2010, the Company's stockholders approved an amendment to the 2008 Plan to increase the number of authorized shares of common stock available for issuance by 3,275,000 shares to 6,855,000 shares. As of June 30, 2012, there were 1,733,002 shares that remained available for grant under the 2008 Plan. BioScrip/CHS Equity Plan Effective upon closing of the acquisition of CHS, the CHS 2006 Equity Incentive Plan was adopted by the Company and renamed the “BioScrip/CHS 2006 Equity Incentive Plan” (as amended and restated, the “BioScrip/CHS Plan”). There were 13,000,000 shares of CHS common stock originally authorized for issuance under the CHS 2006 Equity Incentive Plan, which were converted into 3,106,315 shares of BioScrip common stock, and adjusted using the exchange ratio defined by the merger agreement. The Board of Directors further amended the BioScrip/CHS Plan to provide for it to have substantially the same terms and provisions as the 2008 Plan. Of the options authorized and outstanding under the BioScrip/CHS Plan on the date of the acquisition, 716,086 options were designated as “rollover” options. These rollover options were issued to the top five executives of CHS at the time of the acquisition, and otherwise remain subject to the term of the BioScrip/CHS Plan, as amended, and fully vested on the date of conversion. Under the terms of the BioScrip/CHS Plan, any shares of BioScrip common stock subject to rollover options that expire or otherwise terminate before all or any part of the shares subject to such options have been purchased as a result of the exercise of such options shall remain available for issuance under the BioScrip/CHS Plan. The remaining 2,390,229 shares are authorized for issuance under the BioScrip/CHS Plan. These shares may be used for awards under the BioScrip/CHS Plan, provided that awards using such available shares are not made after the date that awards or grants could have been made under the terms of the pre-existing plan, and are only made to individuals who were not employees or directors of BioScrip or an affiliate or subsidiary of BioScrip prior to such acquisition. As of June 30, 2012, there were 1,870,779 shares that remained available under the BioScrip/CHS Plan. Stock Options The Company recognized compensation expense related to stock options of $1.5 million and $0.8 million during the three months ended June 30, 2012 and 2011, respectively. The Company recognized compensation expense related to stock options of $2.2 million and $1.8 million during the six months ended June 30, 2012 and 2011, respectively. Restricted Stock The Company recognized compensation expense related to restricted stock awards of $0.1 million and $0.2 million during the three months ended June 30, 2012 and 2011, respectively. The Company recognized compensation expense related to restricted stock awards of $0.2 million and $0.3 million during the six months ended June 30, 2012 and 2011, respectively. Stock Appreciation Rights The Company recognized compensation expense related to stock appreciation rights awards of $0.2 million and $0.1 million during the three months ended June 30, 2012 and 2011, respectively. The Company recognized compensation expense related to stock appreciation rights awards of $0.3 million and $0.1 million during the six months ended June 30, 2012 and 2011, respectively.

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 123R
-Paragraph 64, 65, A240
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Statement of Position (SOP)
-Number 93-6
-Paragraph 53
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 14

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 50
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6406099&loc=d3e25284-112666

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5444-113901

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 40
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6418621&loc=d3e17540-113929

+ Details

SUBSEQUENT EVENTS	6 Months Ended
SUBSEQUENT EVENTS	Jun. 30, 2012
Subsequent Events [Abstract]
Subsequent Events [Text Block]	SUBSEQUENT EVENTS On July 3, 2012, the Company entered into a Third Amendment to the Second Amendment and Restated Credit Agreement, by and among the Company, as borrower, all of its subsidiaries as guarantors thereto, the lenders, Healthcare Finance Group, LLC, an administrative agent, and the other parties thereto. The amendment reduces revolving commitments from $150 million to $125 million; reduces the minimum revolving balance from $30 million to zero; increases the basket limitation for loans and advances to third parties and investments in permitted joint ventures to $60 million; removes the dollar limitation on permitted acquisitions so long as the proposed acquisition meets the pro forma and other conditions; lowers the LIBOR floor to 1.00% from 1.25%; and modifies the definition of the term “Consolidated EBITDA”. On July 31, 2012, the Company acquired InfuScience, Inc. (“InfuScience”) for a cash payment of $38.0 million. The purchase price could increase to $41.0 million based on the results of operations during the 24 month period following the closing. Headquartered in Gurnee, IL, InfuScience acquires, develops and operates businesses providing alternate site infusion pharmacy services. InfuScience has five infusion centers located in Eagan, Minnesota; Lincoln and Omaha, Nebraska; Chantilly, Virginia; Charleston, South Carolina; and Savannah, Georgia.

DISCONTINUED OPERATIONS (Tables)

6 Months Ended

Jun. 30, 2012

DISCONTINUED OPERATIONS [Abstract]

charges associated with exit or disposal activity [Table Text Block]

The accrual activity consisted of the following (in thousands):



	Impairment Costs			Employee Severance and Other Benefits			Facility-Related Costs		Other Costs			Total
Liability balance as of December 31, 2011	$	—		$	—		$	—	$	—		$	—
Expenses	5,839			5,349			1,071		773			13,032
Cash payments	—			(3,885		)	—		(2,579		)	(6,464		)
Non-cash charges	$	(5,839	)	$	—		$	—	$	2,024		$	(3,815	)
Liability balance as of June 30, 2012	$	—		$	1,464		$	1,071	$	218		$	2,753

Schedule of Disposal Groups, Including Discontinued Operations, Income Statement, Balance Sheet and Additional Disclosures [Table Text Block]

, the carrying value of the assets included in the Pharmacy Services Asset Sale was as follows (in thousands):



Inventory	$	30,560
Prepaid expenses and other current assets	299
Total current assets	30,859
Property and equipment, net	1,592
Goodwill	11,754
Intangible assets, net	2,503
Total assets	$	46,708



Discontinued Operations Results
(in thousands)

	Three Months Ended June 30,						Six Months Ended June 30,
	2012			2011			2012			2011

Revenue	$	128,436		$	309,829		$	466,539		$	618,289

Gross profit	$	7,078		$	24,388		$	30,038		$	50,300

Gross profit as a percentage of revenue	5.5		%	7.9		%	6.4		%	8.1		%

Gain on sale, before income taxes	$	100,012		$	—		$	100,012		$	—

Impairment costs, employee severance and other benefit-related costs, and other one-time charges	$	(13,032	)	$	—		$	(13,032	)	$	—

(Loss) income from discontinued operations, net of income taxes	$	76,059		$	(686	)	$	75,379		$	3,270

- Definition

Tabular disclosure of disposal groups, which may include the gain (loss) recognized in the income statement and the income statement caption that includes that gain (loss), amounts of revenues and pretax profit or loss reported in discontinued operations, the classification and carrying value of the assets and liabilities comprising the disposal group, and the segment in which the disposal group was reported. Also may include the amount of adjustments to amounts previously reported in discontinued operations such as resolution of contingencies arising from the disposal transaction or the operations of the component prior to disposal.

+ References + Details

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

6 Months Ended

Jun. 30, 2012

Accounting Policies [Abstract]

Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]

The following table sets forth the computation of basic and diluted income (loss) per common share (in thousands, except for per share amounts):



	Three Months Ended June 30,						Six Months Ended June 30,
	2012			2011			2012			2011
Numerator:
Loss from continuing operations, net of income taxes	$	(4,293	)	$	(1,640	)	$	(6,316	)	$	(2,655	)
(Loss) income from discontinued operations, net of income taxes	76,059			(686		)	75,379			3,270
Net income (loss)	$	71,766		$	(2,326	)	$	69,063		$	615

Denominator - Basic:
Weighted average number of common shares outstanding	55,746			54,298			55,143			54,216

Basic loss from continuing operations	$	(0.07	)	$	(0.03	)	$	(0.11	)	$	(0.05	)
Basic (loss) income from discontinued operations	1.36			(0.01		)	1.36			0.06
Basic (loss) income	$	1.29		$	(0.04	)	$	1.25		$	0.01

Denominator - Diluted:
Weighted average number of common shares outstanding	55,746			54,298			55,143			54,216
Common share equivalents of outstanding stock options and restricted awards	—			—			—			—
Total diluted shares outstanding	55,746			54,298			55,143			54,216

Diluted loss from continuing operations	$	(0.07	)	$	(0.03	)	$	(0.11	)	$	(0.05	)
Diluted income (loss) from discontinued operations	1.36			(0.01		)	1.36			0.06
Diluted income (loss)	$	1.29		$	(0.04	)	$	1.25		$	0.01

GOODWILL AND INTANGIBLE ASSETS (Tables)

6 Months Ended

Jun. 30, 2012

NOTE 4 – GOODWILL AND INTANGIBLE ASSETS [Abstract]

Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]

Amortization expense is expected to be the following (in thousands):



2012 (six months)	$	1,822
2013	836
Total	$	2,658

Schedule of Goodwill [Table Text Block]

Goodwill consisted of the following as of June 30, 2012 and December 31, 2011 (in thousands):



	June 30, 2012		December 31, 2011
Infusion	$	265,859	$	265,859
Home Health Services	33,784		33,784
PBM Services	12,744		12,744
Total	$	312,387	$	312,387

Schedule of Intangible Assets by Major Class [Table Text Block]

Intangible assets consisted of the following as of June 30, 2012 and December 31, 2011 (in thousands):



		June 30, 2012
	Estimated Useful Life	Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount
Indefinite Lived Assets
Certificates of need	indefinite	$	9,600	$	—		$	9,600
Nursing trademarks	indefinite	5,800		—			5,800
		15,400		—			15,400
Definite Lived Assets
Customer list	6 - 16 months	512		(219		)	293
Infusion trademarks	3 years	2,600		(1,973		)	627
Infusion customer relationships	3 years	7,200		(5,462		)	1,738
		10,312		(7,654		)	2,658
		$	25,712	$	(7,654	)	$	18,058

schedule of intangible assets by major class, prior year [Table Text Block]



		December 31, 2011
	Estimated Useful Life	Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount
Indefinite Lived Assets
Certificates of need	indefinite	$	9,600	$	—		$	9,600
Nursing trademarks	indefinite	5,800		—			5,800
		15,400		—			15,400
Definite Lived Assets
Customer list	6 months	319		(101		)	218
Infusion trademarks	3 years	2,600		(1,538		)	1,062
Infusion customer relationships	3 years	7,200		(4,258		)	2,942
		10,119		(5,897		)	4,222
		$	25,519	$	(5,897	)	$	19,622

- Definition

Tabular disclosure of goodwill by reportable segment and in total. Disclosure details may include, but are not limited to, the carrying amount of goodwill, goodwill acquired during the year, goodwill impairment losses recognized, goodwill written-off due to the sale of a business unit, goodwill not yet allocated, and any other changes to goodwill.

+ References + Details

RESTRUCTURING EXPENSE (Tables)

6 Months Ended

Jun. 30, 2012

Restructuring and Related Activities [Abstract]

Schedule of Restructuring Reserve by Type of Cost [Table Text Block]

The restructuring accrual activity consisted of the following (in thousands):



	Employee Severance and Other Benefits			Consulting Costs			Facility-Related Costs			Other Costs		Total
Liability balance as of December 31, 2011	$	2,109		$	50		$	1,289		$	—	$	3,448
Expenses	—			300			—			—		300
Cash payments	(1,234		)	(40		)	(223		)	—		(1,497		)
Liability balance as of June 30, 2012	$	875		$	310		$	1,066		$	—	$	2,251

PROPERTY AND EQUIPMENT (Tables)

6 Months Ended

Jun. 30, 2012

Property, Plant and Equipment [Abstract]

Property, Plant and Equipment [Table Text Block]

Property and equipment consisted of the following (in thousands):



	June 30, 2012			December 31, 2011
Computer and office equipment, including equipment acquired under capital leases	$	13,653		$	15,684
Software capitalized for internal use	9,587			15,520
Vehicles, including equipment acquired under capital leases	1,725			1,701
Medical equipment	14,832			14,698
Work in progress	1,240			2,813
Furniture and fixtures	3,102			3,626
Leasehold improvements	7,226			6,507
	51,365			60,549
Less: Accumulated depreciation	(30,508		)	(33,598		)
Property and equipment, net	$	20,857		$	26,951

DEBT (Tables)

6 Months Ended

Jun. 30, 2012

Debt Disclosure [Abstract]

Schedule of Debt [Table Text Block]

As of June 30, 2012 the Company’s long-term debt consisted of the following obligations (in thousands):



Revolving credit facility	$	30,000
Senior unsecured notes	225,000
Capital leases	2,446
	257,446
Less - obligations maturing within one year	31,230
Long term debt - net of current portion	$	226,216

COMMITMENTS AND CONTINGENCIES (Tables)

6 Months Ended

Jun. 30, 2012

Commitments and Contingencies Disclosure [Abstract]

Schedule of future minimum lease payments for operating and capital leases [Table Text Block]

As of June 30, 2012, future minimum lease payments, including interest, under operating and capital leases are as follows (in thousands):



	Operating Leases		Capital Leases		Total
2012 (six months)	$	3,060	$	1,160	$	4,220
2013	4,620		1,038		5,658
2014	3,307		198		3,505
2015	2,686		165		2,851
2016	2,188		3		2,191
2017 and thereafter	3,770		—		3,770
Total	$	19,631	$	2,564	$	22,195

OPERATING AND REPORTABLE SEGMENTS (Tables)

6 Months Ended

Jun. 30, 2012

Segment Reporting [Abstract]

Schedule of Segment Reporting Information, by Segment [Table Text Block]

Segment Reporting Information

(in thousands)



	Three Months Ended June 30,						Six Months Ended June 30,
	2012			2011			2012			2011
Results of Operations:
Revenue:
Infusion Services - product revenue	$	108,557		$	87,717		$	215,360		$	177,499
Infusion Services - service revenue	2,416			2,136			4,667			4,079
Total Infusion Services revenue	110,973			89,853			220,027			181,578

Home Health Services - service revenue	16,860			17,673			33,571			34,881

PBM Services - service revenue	28,068			24,049			57,936			45,953

Total revenue	$	155,901		$	131,575		$	311,534		$	262,412

Adjusted EBITDA by Segment before corporate overhead:
Infusion Services	$	8,026		$	8,340		$	15,809		$	17,624
Home Health Services	1,075			1,787			2,155			2,793
PBM Services	6,364			6,764			12,462			12,887
Total Segment Adjusted EBITDA	15,465			16,891			30,426			33,304

Corporate overhead	(6,458		)	(5,362		)	(13,040		)	(12,012		)

Interest expense, net	(6,790		)	(6,235		)	(13,359		)	(12,847		)
Income tax (expense) benefit	(364		)	127			138			544
Depreciation	(2,050		)	(1,647		)	(3,981		)	(2,980		)
Amortization of intangibles	(878		)	(819		)	(1,757		)	(1,638		)
Stock-based compensation expense	(1,745		)	(1,120		)	(2,711		)	(2,252		)
Acquisition, integration, severance and other employee costs	(1,271		)	—			(1,530		)	—
Restructuring expense	(202		)	(3,475		)	(502		)	(4,774		)
Loss from continuing operations, net of income taxes	$	(4,293	)	$	(1,640	)	$	(6,316	)	$	(2,655	)

Supplemental Operating Data
							June 30, 2012			December 31, 2011
Total Assets
Infusion Services							$	366,198		$	353,999
Home Health Services							66,557			64,672
PBM Services							39,756			40,418
Corporate unallocated, including cash and cash equivalents							169,996			22,615
Assets from discontinued operations							—			59,005
Assets associated with discontinued operations, not sold							32,411			136,393
Total							$	674,918		$	677,102

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References + Details

INCOME TAXES (Tables)

6 Months Ended

Jun. 30, 2012

Income Tax Disclosure [Abstract]

Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]



	Three Months Ended June 30,						Six Months Ended June 30,
	2012			2011			2012			2011
Tax benefit at statutory rate	$	(1,375	)	$	(619	)	$	(2,258	)	$	(1,120	)
State tax benefit, net of Federal taxes	(223		)	(92		)	(364		)	(165		)
Change in tax contingencies	5			8			11			13
Valuation allowance changes affecting income tax expense	2,353			514			2,949			607
Other	(396		)	62			(476		)	121
Income tax expense (benefit)	$	364		$	(127	)	$	(138	)	$	(544	)

components of income tax [Table Text Block]

The Company’s Federal and state income tax benefit from continuing operations is summarized in the following table (in thousands):



	Three Months Ended June 30,						Six Months Ended June 30,
	2012			2011			2012			2011
Current
Federal	$	(120	)	$	(28	)	$	(149	)	$	(273	)
State	184			(6		)	11			(128		)
Total Current	64			(34		)	(138		)	(401		)
Deferred
Federal	262			(81		)	—			(125		)
State	38			(12		)	—			(18		)
Total deferred	300			(93		)	—			(143		)
Total income tax expense (benefit)	$	364		$	(127	)	$	(138	)	$	(544	)

BASIS OF PRESENTATION affiliate (Details) - USD ($) $ in Thousands	Jun. 30, 2012	Dec. 31, 2011
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures	$ 6,949	$ 0

DISCONTINUED OPERATIONS (Details)	3 Months Ended		6 Months Ended
DISCONTINUED OPERATIONS (Details)	Jun. 30, 2012 USD ($)	Jun. 30, 2011 USD ($)	Jun. 30, 2012 USD ($)	Jun. 30, 2011 USD ($)	May 04, 2012 USD ($)	Dec. 31, 2011 USD ($)
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
One time costs related to pharmacy services asset sale reserve	$ 2,753,000		$ 2,753,000			$ 0
total purchase price at closing, including the value of inventories on hand attributable to the operations subject to the Pharmacy Services Asset Sale.			158,800,000
Amoun the company has received as a result of events related directly or indirectly to the Buyers' retention of certain business after the closing			740,000
Additional purchase price the company may receive related directly or indirectly to the Buyers' retention of certain business after the closing			15,000,000
Amount the company may be required to refund related directly or indirectly to the Buyers' retention of certain business after the closing			6,400,000
Accounts receivable and working capital liabilities relating to the operations subject to the Pharmacy Services Asset Sale	32,400,000		32,400,000
Discontinued Operation, Gain (Loss) from Disposal of Discontinued Operation, before Income Tax	100,012,000	$ 0	100,012,000	$ 0
Disposal transaction costs			5,600,000
restructuring costs, transaction costs, and other one-time charges as a result of the transaction	(13,032,000)	0	(13,032,000)	0
discontinued operation, gain from disposal of discontinued operation, before incaome tax, net of restructuring costs, transaction costs, and other one-time charges as a result of the transaction			87,000,000
Amount the company received as the result of an agreement which provided that BioScrip ceased to be the sole fulfillment pharmacy for customers who came through the drugstore.com website			3,000,000
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability			2,900,000
Disposal Group, Including Discontinued Operation, Interest Expense	200,000	1,000,000	900,000	1,600,000
Receivables, less allowance for doubtful accounts	146,469,000		146,469,000			225,412,000
Revenue	128,436,000	309,829,000	466,539,000	618,289,000
Inventory					$ 30,560,000
Prepaid expenses and other current assets					299,000
Total current assets	0		0		30,859,000	38,876,000
Property and equipment, net					1,592,000
Goodwill					11,754,000
Intangible assets, net					2,503,000	5,600,000
Gross profit	$ 7,078,000	$ 24,388,000	$ 30,038,000	$ 50,300,000
Gross profit as a percentage of revenue	0.00%	0.00%	0.00%	0.00%
(Loss) income from discontinued operations, net of income taxes	$ 76,059,000	$ (686,000)	$ 75,379,000	$ 3,270,000
Inventory	21,242,000		21,242,000			17,997,000
Prepaid expenses and other current assets	5,725,000		5,725,000			10,184,000
Total current assets	311,859,000		311,859,000			292,469,000
Property and equipment, net	20,857,000		20,857,000			26,951,000
Other non-current assets	1,455,000		1,455,000			1,552,000
Total assets	674,918,000	677,102,000	674,918,000	677,102,000		677,102,000
Current portion of long-term debt	31,230,000		31,230,000			66,161,000
Accounts payable	28,842,000		28,842,000			79,155,000
Amounts due to plan sponsors	25,681,000		25,681,000			25,219,000
Accrued expenses and other current liabilities	36,493,000		36,493,000			32,648,000
Total current liabilities	138,997,000		138,997,000			220,774,000
Long-term debt, net of current portion	226,216,000		226,216,000			227,298,000
Other non-current liabilities	5,798,000		5,798,000			3,456,000
Total liabilities	380,019,000		380,019,000			461,823,000
Discontinued Operation, Tax Effect of Discontinued Operation	$ 5,100,000	$ 200,000	5,100,000	$ 400,000
Assets of Disposal Group, Including Discontinued Operation					$ 46,708,000
one time costs related to pharmacy services asset sale reserve, settled in cash			(6,464,000)
one time costs related to pharmacy services asset sale reserve, noncash			$ (3,815,000)
community pharmacy [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of locations	27		27
certain assets	3		3
mail order [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of locations	3		3
locations not tranferred as part of sale	2		2
Impairment in Value of Asset [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
One time costs related to pharmacy services asset sale reserve	$ 0		$ 0			0
restructuring costs, transaction costs, and other one-time charges as a result of the transaction			(5,839,000)
one time costs related to pharmacy services asset sale reserve, settled in cash			0
one time costs related to pharmacy services asset sale reserve, noncash			(5,839,000)
Employee Severance [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
One time costs related to pharmacy services asset sale reserve	1,464,000		1,464,000			0
restructuring costs, transaction costs, and other one-time charges as a result of the transaction			(5,349,000)
one time costs related to pharmacy services asset sale reserve, settled in cash			(3,885,000)
one time costs related to pharmacy services asset sale reserve, noncash			0
Facility Closing [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
One time costs related to pharmacy services asset sale reserve	1,071,000		1,071,000			0
restructuring costs, transaction costs, and other one-time charges as a result of the transaction			(1,071,000)
one time costs related to pharmacy services asset sale reserve, settled in cash			0
one time costs related to pharmacy services asset sale reserve, noncash			0
Other [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
One time costs related to pharmacy services asset sale reserve	$ 218,000		218,000			$ 0
restructuring costs, transaction costs, and other one-time charges as a result of the transaction			(773,000)
one time costs related to pharmacy services asset sale reserve, settled in cash			(2,579,000)
one time costs related to pharmacy services asset sale reserve, noncash			$ 2,024,000

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2012 USD ($) $ / shares $ / warrant shares	Jun. 30, 2011 USD ($) $ / shares shares	Jun. 30, 2012 USD ($) $ / shares $ / warrant shares	Jun. 30, 2011 USD ($) $ / shares shares
Numerator:
Loss from continuing operations, net of income taxes \| $	$ (4,293)	$ (1,640)	$ (6,316)	$ (2,655)
Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest \| $	76,059	(686)	75,379	3,270
Net income (loss) \| $	$ 71,766	$ (2,326)	$ 69,063	$ 615
Denominator - Basic:
Weighted Average Number of Shares Outstanding, Basic \| shares	55,746	54,298	55,143	54,216
Income (Loss) from Continuing Operations, Per Basic Share	$ (0.07)	$ (0.03)	$ (0.11)	$ (0.05)
Income (Loss) from Discontinued Operations, Net of Tax, Per Basic Share	1.36	(0.01)	1.36	0.06
Earnings Per Share, Basic	$ 1.29	$ (0.04)	$ 1.25	$ 0.01
Denominator - Diluted:
Common share equivalents of outstanding stock options and restricted awards \| shares	0	0	0	0
Weighted Average Number of Shares Outstanding, Diluted \| shares	55,746	54,298	55,143	54,216
Income (Loss) from Continuing Operations, Per Diluted Share	$ (0.07)	$ (0.03)	$ (0.11)	$ (0.05)
Income (Loss) from Discontinued Operations, Net of Tax, Per Diluted Share	1.36	(0.01)	1.36	0.06
Earnings Per Share, Diluted	$ 1.29	$ (0.04)	$ 1.25	$ 0.01
Antidilutive warrants excluded from computation of earnings per share, amount \| shares	3,400		3,400
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / warrant	10		10
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount \| shares	5,600	6,900	5,600	6,900

GOODWILL AND INTANGIBLE ASSETS (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2012	Jun. 30, 2011	Jun. 30, 2012	Jun. 30, 2011	May 04, 2012	Dec. 31, 2011
intangible assets, line items [Line Items]
Disposal Group, Including Discontinued Operation, Intangible Assets, Net					$ 2,503	$ 5,600
Amortization of Intangible Assets	$ 878	$ 819	$ 1,757	$ 1,638
indefinite lived intangible assets, gross	15,400		15,400			15,400
Indefinite-Lived Intangible Assets (Excluding Goodwill)	15,400		15,400			15,400
indefinite lived intangible assets accumulated amortization	0		0			0
Finite-Lived Intangible Assets, Gross	10,312		10,312			10,119
Finite-Lived Intangible Assets, Accumulated Amortization	(7,654)		(7,654)			(5,897)
Finite-Lived Intangible Assets, Net	2,658		2,658			4,222
intangible assets, gross	25,712		25,712			25,519
intangible assets, accumulated amortization	(7,654)		(7,654)			(5,897)
Intangible Assets, Net (Excluding Goodwill)	18,058		18,058			19,622
Future Amortization Expense, Remainder of Fiscal Year			1,822
Future Amortization Expense, Year One			836
Finite-Lived Intangible Assets, Future Amortization Expense			2,658
certificates of need [Member]
intangible assets, line items [Line Items]
indefinite lived intangible assets, gross	9,600		9,600			9,600
Indefinite-Lived Intangible Assets (Excluding Goodwill)	9,600		9,600			9,600
indefinite lived intangible assets accumulated amortization	0		0			0
nursing trademark [Member]
intangible assets, line items [Line Items]
indefinite lived intangible assets, gross	5,800		5,800			5,800
Indefinite-Lived Intangible Assets (Excluding Goodwill)	5,800		5,800			5,800
indefinite lived intangible assets accumulated amortization	0		0			0
Customer Lists [Member]
intangible assets, line items [Line Items]
Finite-Lived Intangible Assets, Gross	512		512			319
Finite-Lived Intangible Assets, Accumulated Amortization	(219)		(219)			(101)
Finite-Lived Intangible Assets, Net	293		293			218
infustion trademarks [Member]
intangible assets, line items [Line Items]
Finite-Lived Intangible Assets, Gross	2,600		2,600			2,600
Finite-Lived Intangible Assets, Accumulated Amortization	(1,973)		(1,973)			(1,538)
Finite-Lived Intangible Assets, Net	627		627			1,062
Customer Relationships [Member]
intangible assets, line items [Line Items]
Finite-Lived Intangible Assets, Gross	7,200		7,200			7,200
Finite-Lived Intangible Assets, Accumulated Amortization	(5,462)		(5,462)			(4,258)
Finite-Lived Intangible Assets, Net	$ 1,738		$ 1,738			$ 2,942

GOODWILL AND INTANGIBLE ASSETS Goodwill rollforward (Details) - USD ($) $ in Thousands	Jun. 30, 2012	Dec. 31, 2011
Goodwill [Line Items]
Goodwill	$ 312,387	$ 312,387
Infusion Services [Member]
Goodwill [Line Items]
Goodwill	265,859	265,859
Home Health Services [Member]
Goodwill [Line Items]
Goodwill	33,784	33,784
PBM Services [Member]
Goodwill [Line Items]
Goodwill	$ 12,744	$ 12,744

- Definition

Carrying amount as of the balance sheet date, which is the cumulative amount paid and (if applicable) the fair value of any noncontrolling interest in the acquiree, adjusted for any amortization recognized prior to the adoption of any changes in generally accepted accounting principles (as applicable) and for any impairment charges, in excess of the fair value of net assets acquired in one or more business combination transactions.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 142
-Paragraph 45
-Subparagraph e
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 142
-Paragraph 43
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141R
-Paragraph 68
-Subparagraph l
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6388280&loc=d3e13770-109266

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6905597&loc=d3e13816-109267

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141R
-Paragraph 72
-Subparagraph d
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 142
-Paragraph 45
-Subparagraph e
-Clause 1
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141R
-Paragraph 34
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

RESTRUCTURING EXPENSE restructuring expense overview (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		21 Months Ended
	Jun. 30, 2012	Jun. 30, 2011	Jun. 30, 2012	Jun. 30, 2011	Jun. 30, 2012	Dec. 31, 2011
Restructuring Cost and Reserve [Line Items]
Restructuring Charges	$ 202	$ 3,475	$ 502	$ 4,774
Phase I [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Charges		3,500	300	4,800	$ 10,200
Restructuring Reserve	2,251		2,251		2,251	$ 3,448
Phase I [Member] \| Employee Severance [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Charges		1,200	0	1,500	4,200
Restructuring Reserve	875		875		875	2,109
Phase I [Member] \| Consulting [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Charges		$ 1,700	300	$ 2,700	4,400
Restructuring Reserve	310		310		310	50
Phase I [Member] \| Facility Closing [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Charges			0		1,600
Restructuring Reserve	1,066		1,066		1,066	1,289
Phase I [Member] \| other restructuring costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Charges	600		0
Restructuring Reserve	0		0		0	0
Phase II [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Charges	200		202		202
Restructuring Reserve	195		195		195	0
Phase II [Member] \| Employee Severance [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Charges	200		202		202
Restructuring Reserve	195		195		195	0
Phase II [Member] \| Consulting [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Charges			0
Restructuring Reserve	0		0		0	0
Phase II [Member] \| Facility Closing [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Charges			0
Restructuring Reserve	0		0		0	0
Phase II [Member] \| other restructuring costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Charges			0
Restructuring Reserve	$ 0		$ 0		$ 0	$ 0

RESTRUCTURING EXPENSE restructuring accrual activity (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		21 Months Ended
	Jun. 30, 2012	Jun. 30, 2011	Jun. 30, 2012	Jun. 30, 2011	Jun. 30, 2012	Dec. 31, 2011
Restructuring Cost and Reserve [Line Items]
Restructuring Charges	$ 202	$ 3,475	$ 502	$ 4,774
Phase II [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	195		195		$ 195	$ 0
Restructuring Charges	200		202		202
Restructuring Reserve, Settled with Cash			(7)
Phase II [Member] \| Employee Severance [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	195		195		195	0
Restructuring Charges	200		202		202
Restructuring Reserve, Settled with Cash			(7)
Phase II [Member] \| Consulting [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	0		0		0	0
Restructuring Charges			0
Restructuring Reserve, Settled with Cash			0
Phase II [Member] \| Facility Closing [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	0		0		0	0
Restructuring Charges			0
Restructuring Reserve, Settled with Cash			0
Phase II [Member] \| other restructuring costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	0		0		0	0
Restructuring Charges			0
Restructuring Reserve, Settled with Cash			0
Phase I [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	2,251		2,251		2,251	3,448
Restructuring Charges		3,500	300	4,800	10,200
Restructuring Reserve, Settled with Cash			(1,497)
Phase I [Member] \| Employee Severance [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	875		875		875	2,109
Restructuring Charges		1,200	0	1,500	4,200
Restructuring Reserve, Settled with Cash			(1,234)
Phase I [Member] \| Consulting [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	310		310		310	50
Restructuring Charges		$ 1,700	300	$ 2,700	4,400
Restructuring Reserve, Settled with Cash			(40)
Phase I [Member] \| Facility Closing [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	1,066		1,066		1,066	1,289
Restructuring Charges			0		1,600
Restructuring Reserve, Settled with Cash			(223)
Phase I [Member] \| other restructuring costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	0		0		$ 0	$ 0
Restructuring Charges	$ 600		0
Restructuring Reserve, Settled with Cash			$ 0

PROPERTY AND EQUIPMENT (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
PROPERTY AND EQUIPMENT (Details) - USD ($) $ in Thousands	Jun. 30, 2012	Jun. 30, 2011	Jun. 30, 2012	Jun. 30, 2011	Dec. 31, 2011
Property, Plant and Equipment [Abstract]
Impairment of Long-Lived Assets to be Disposed of	$ 5,800
Computer and office equipment, including equipment acquired under capital leases	13,653		$ 13,653		$ 15,684
Depreciation	2,050	$ 1,647	3,981	$ 2,980
Capitalized Computer Software, Amortization	500	$ 700	1,200	$ 1,300
Software capitalized for internal use	9,587		9,587		15,520
Vehicles, including equipment acquired under capital leases	1,725		1,725		1,701
Medical equipment	14,832		14,832		14,698
Work in progress	1,240		1,240		2,813
Furniture and fixtures	3,102		3,102		3,626
Leasehold improvements	7,226		7,226		6,507
Property, Plant and Equipment, Gross	51,365		51,365		60,549
Less: Accumulated depreciation	(30,508)		(30,508)		(33,598)
Property and equipment, net	$ 20,857		$ 20,857		$ 26,951

DEBT (Details) - USD ($) $ in Thousands	Jun. 30, 2012	Dec. 31, 2011
Debt Disclosure [Abstract]
Revolving credit facility	$ 30,000
Senior unsecured notes	225,000
Capital leases	2,446
long term debt and capital lease obligations, total	257,446
Long-term Debt and Capital Lease Obligations, Current	31,230	$ 66,161
Long-term Debt and Capital Lease Obligations	226,216	$ 227,298
Senior notes, fair value disclosure	$ 259,700

COMMITMENTS AND CONTINGENCIES (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2012	Jun. 30, 2011	Dec. 31, 2012	Jun. 30, 2012	Jun. 30, 2011
future minimum payments due [Line Items]
Large PBM Services customer late payment	$ 6,800			$ 6,800
Operating Leases, Future Minimum Payments Due, Current	3,060			3,060
Capital Leases, Future Minimum Payments Due, Current	1,160			1,160
future minimum payments due, current	4,220			4,220
Operating Leases, Future Minimum Payments, Due in Two Years	4,620			4,620
Capital Leases, Future Minimum Payments Due in Two Years	1,038			1,038
future minimum payments due in two years	5,658			5,658
Operating Leases, Future Minimum Payments, Due in Three Years	3,307			3,307
Capital Leases, Future Minimum Payments Due in Three Years	198			198
future minimum payments due in three years	3,505			3,505
Operating Leases, Future Minimum Payments, Due in Four Years	2,686			2,686
Capital Leases, Future Minimum Payments Due in Four Years	165			165
future minimum payments due in four years	2,851			2,851
Operating Leases, Future Minimum Payments, Due in Five Years	2,188			2,188
Capital Leases, Future Minimum Payments Due in Five Years	3			3
future minimum payments due in five years	2,191			2,191
Operating Leases, Future Minimum Payments, Due Thereafter	3,770			3,770
Capital Leases, Future Minimum Payments Due Thereafter	0			0
future minimum leases due thereafter	3,770			3,770
Operating Leases, Future Minimum Payments Due	19,631			19,631
Capital Leases, Future Minimum Payments Due	2,564			2,564
Operating Leases, Rent Expense	1,400	$ 1,400		2,900	$ 2,800
Long-term Purchase Commitment, Amount			$ 13,500
future minimum payments due	$ 22,195			$ 22,195
Minimum [Member]
future minimum payments due [Line Items]
capital lease interest rate	0.00%			0.00%
Maximum [Member]
future minimum payments due [Line Items]
capital lease interest rate	0.00%			0.00%

COMMITMENTS AND CONTINGENCIES Legal Settlement (Details) - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Jun. 30, 2012	Dec. 31, 2011
Commitments and Contingencies Disclosure [Abstract]
Litigation Settlement, Expense	$ 0.3	$ 4.8
Estimated Litigation Liability	$ 5.1	$ 4.8

OPERATING AND REPORTABLE SEGMENTS (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2012	Jun. 30, 2011	Jun. 30, 2012	Jun. 30, 2011	Dec. 31, 2011
Segment Reporting Information [Line Items]
Sales Revenue, Goods, Gross	$ 108,557	$ 87,717	$ 215,360	$ 177,499
Sales Revenue, Services, Other	47,344	43,858	96,174	84,913
Revenue	155,901	131,575	311,534	262,412
Adjusted EBITDA	15,465	16,891	30,426	33,304
Interest Expense	(6,790)	(6,235)	(13,359)	(12,847)
Income Tax Expense (Benefit)	(364)	127	138	544
Depreciation	(2,050)	(1,647)	(3,981)	(2,980)
Amortization of Intangible Assets	(878)	(819)	(1,757)	(1,638)
Share-based Compensation	(1,745)	(1,120)	(2,711)	(2,252)
Acquisition, integration, severance and other employee costs	(1,271)	0	(1,530)	0
Restructuring Charges	(202)	(3,475)	(502)	(4,774)
Loss from continuing operations, net of income taxes	(4,293)	(1,640)	(6,316)	(2,655)
Assets	674,918	677,102	674,918	677,102	$ 677,102
Infusion Services [Member]
Segment Reporting Information [Line Items]
Sales Revenue, Goods, Gross	108,557	87,717	215,360	177,499
Sales Revenue, Services, Other	2,416	2,136	4,667	4,079
Revenue	110,973	89,853	220,027	181,578
Adjusted EBITDA	8,026	8,340	15,809	17,624
Assets	366,198	353,999	366,198	353,999
Home Health Services [Member]
Segment Reporting Information [Line Items]
Sales Revenue, Services, Other	16,860	17,673	33,571	34,881
Adjusted EBITDA	1,075	1,787	2,155	2,793
Assets	66,557	64,672	66,557	64,672
PBM Services [Member]
Segment Reporting Information [Line Items]
Sales Revenue, Services, Other	28,068	24,049	57,936	45,953
Adjusted EBITDA	6,364	6,764	12,462	12,887
Assets	39,756	40,418	39,756	40,418
Corporate [Member]
Segment Reporting Information [Line Items]
Adjusted EBITDA	(6,458)	(5,362)	(13,040)	(12,012)
Assets	169,996	22,615	169,996	22,615
Assets from discontinued operations [Member]
Segment Reporting Information [Line Items]
Assets	0	59,005	0	59,005
Assets associated with discontinued operations, not sold [Member]
Segment Reporting Information [Line Items]
Assets	$ 32,411	$ 136,393	$ 32,411	$ 136,393

CONCENTRATION OF RISK (Details)	3 Months Ended		6 Months Ended
CONCENTRATION OF RISK (Details)	Jun. 30, 2012	Jun. 30, 2011	Jun. 30, 2012	Jun. 30, 2011
Customer Concentration Risk [Member]
Concentration Risk [Line Items]
Concentration of Risk, Percentage	18.00%	19.00%	17.00%	18.00%
Product Concentration Risk [Member]
Concentration Risk [Line Items]
Concentration of Risk, Percentage	20.00%	26.00%	21.00%	26.00%

INCOME TAXES (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
INCOME TAXES (Details) - USD ($) $ in Thousands	Jun. 30, 2012	Jun. 30, 2011	Jun. 30, 2012	Jun. 30, 2011
Income Tax Disclosure [Abstract]
Current Federal Tax Expense (Benefit)	$ (120)	$ (28)	$ (149)	$ (273)
Current State and Local Tax Expense (Benefit)	184	(6)	11	(128)
Current Income Tax Expense (Benefit)	64	(34)	(138)	(401)
Deferred Federal Income Tax Expense (Benefit)	262	(81)	0	(125)
Deferred State and Local Income Tax Expense (Benefit)	38	(12)	0	(18)
Deferred Income Tax Expense (Benefit)	300	(93)	0	(143)
Income Tax Expense (Benefit)	364	(127)	(138)	(544)
Tax benefit at statutory rate	(1,375)	(619)	(2,258)	(1,120)
State tax benefit, net of Federal taxes	(223)	(92)	(364)	(165)
Change in tax contingencies	5	8	11	13
Valuation allowance changes affecting income tax expense	2,353	514	2,949	607
Other	$ (396)	$ 62	$ (476)	$ 121

STOCK-BASED COMPENSATION (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
STOCK-BASED COMPENSATION (Details) - USD ($) $ in Millions	Jun. 30, 2012	Jun. 30, 2011	Jun. 30, 2012	Jun. 30, 2011
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Stock or Unit Option Plan Expense	$ 1.5	$ 0.8	$ 2.2	$ 1.8
Restricted Stock or Unit Expense	0.1	0.2	0.2	0.3
stock appreciation right expense	$ 0.2	$ 0.1	$ 0.3	$ 0.1
2008 Plan [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Share-based compensation agreement by share-based payment awared, number of shares originally authorized	3,580,000		3,580,000
share-based compensation arrangement by share-based payment awared, adjustment to number of shares authorized	3,275,000		3,275,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	6,855,000		6,855,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	1,733,002		1,733,002
CHS 2006 Equity Incentive Plan [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Share-based compensation agreement by share-based payment awared, number of shares originally authorized	13,000,000		13,000,000
BioScrip/CHS Plan [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Share-based compensation agreement by share-based payment awared, number of shares originally authorized	3,106,315		3,106,315
rollover options	716,086		716,086
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	2,390,229		2,390,229
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	1,870,779		1,870,779

SUBSEQUENT EVENTS (Details)	Jul. 31, 2012 USD ($)	Jul. 03, 2012 USD ($)
Infuscience acquisition [Member]
Subsequent Event [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid	$ 38,000,000
Business Acquisition, Cost of Acquired Entity, Total Potential Cash Paid depending on results	$ 41,000,000
Number of locations	5
line of credit refinancing [Member] \| Third Amendment [Member]
Subsequent Event [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity		$ 125,000,000
line of credit minimum balance		$ 0
line of credit libor floor		0.00%
line of credit refinancing [Member] \| second amendment [Member]
Subsequent Event [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity		$ 150,000,000
line of credit minimum balance		30,000,000
basket limitation for loans and advances to third parties and investments in permitted joint ventures		$ 60,000,000
line of credit libor floor		0.00%